Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +48.45%
#3 Black Phoenix Black Phoenix +34.85%
#4 Velvet Velvet +30.94%
#5 Cross Cross +19.36%
#6 Akedo Akedo +17.98%
#7 DoubleZero DoubleZero +14.50%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.43%
#9 Fake World Assets Fake World Assets +10.49%
#10 Cap Cap +10.24%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Sigyn Therapeutics, Inc. Sigyn Therapeutics, Inc.

Sigyn Therapeutics, Inc.

SIGY
Rank in Stocks #41050
Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise... Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and lipoteichoic acid; various viral pathogens; harmful hepatic toxins; CytoVesicles; and significant pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6. The company is headquartered in San Diego, California.
Share Price
$0.03
Last synced: 2026-08-12
Market Cap
$48.16K
Change (1 day)
-23.08%
Change (1 year)
-98.93%
Country
US
Trade Sigyn Therapeutics, Inc. (SIGY)

Category

Healthcare
Revenue for Sigyn Therapeutics, Inc. (SIGY)
Revenue in Aug 2026 TTM: 0
According to Sigyn Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sigyn Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE